[NEUROSONOGRAPHICAL CHARACTERISTICS OF DYSMATURE INFANTS DEPENDING ON CONDUCTED NEUROPROTECTION]

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Perinatology

Background:

• Preterm delivery (PD) is a significant challenge in modern obstetrics.
• Fetal neuroprotection is a key management strategy for preterm delivery.
• Magnesium sulfate is the primary agent for fetal neuroprotection, though its efficacy is debated.

Purpose of the Study:

• To evaluate the impact of fetal neuroprotection on intraventricular hemorrhage (IVH) in neonates born between 27-28 weeks gestation.
• To assess both the frequency and severity of IVH in relation to neuroprotection management.

Main Methods:

• A study involving 62 neonates from pregnancies delivered at 27-28 weeks gestation.
• Two groups were analyzed: 37 neonates received fetal neuroprotection, while 25 did not.
• Neurosonography was performed on all neonates to quantify and grade IVH.

Main Results:

• Fetal neuroprotection did not significantly decrease the overall incidence of IVH in neonates born at 27-28 weeks.
• A significant reduction in the severity of IVH was observed, with a 2.5-fold decrease in grades 3 or 4 IVH (from 69.2% to 27.7%) in the neuroprotection group.

Conclusions:

• Current fetal neuroprotection strategies, specifically magnesium sulfate, may not prevent IVH in very preterm infants.
• Neuroprotection appears to play a crucial role in mitigating the severity of intraventricular hemorrhage in neonates born at 27-28 weeks gestation.